Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
ArticleAbstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily comparedPalabras claves:aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxabanAutores:Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.Fuentes:googlescopusRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
ArticleAbstract: Background: Direct oral anticoagulants are administered in fixed doses irrespective of body weight,Palabras claves:Cardiovascular Risk, DOAC, prevention, rivaroxabanAutores:Berkowitz S.D., Bhatt D.L., Dyal L., Eikelboom J.W., Fox K.A.A., Guzik T.J., Muehlhofer E., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Ramasundarahettige C., Yusuf S.Fuentes:googlescopusRivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
ArticleAbstract: Background: Coronary artery disease is a major cause of morbidity and mortality worldwide, and is aPalabras claves:Autores:ABIB E., ABRANTES J.A., AHUAD GUERRERO R.A., ALBISU DI GENNERO J.P., ALVAREZ M., Anand S.S., Avezum A.J., Barbieri M., BARTOLACCI I.P., Berkowitz S.D., Bhatt D.L., BORDONAVA A.P., Bosch J.J., Branch K.R.H., CACCAVO A., CARDONA M., CARTASEGNA L.U.I.S., Chacón C., Connolly S.J., Cook-Bruns N., COSTABEL J.P., CUADRADO J., Cuneo C.A., Dagenais G.R., Dans A.M., DEBONNAIRE P., DRAN R.D., DUJARDIN K.A.R.L., Dyal L., ECTOR B.A.V.O., Eikelboom J.W., ELEGEERT I.V.A.N., Felix Camilo, FERRE PACORA F.A., Fox K.A.A., GARCIA DURAN R.O., GARRIDO M., Gomez Vilamajo O., GONZALEZ COLASO P.D.C., GRINFELD D., Guzik T.J., GUZMAN L.U.I.S., Ha J.W., HASBANI E., HERNANDES M., HOFFER E., HOMINAL M.A., Hori M., HRABAR A., IBANEZ SAGGIA L.M., INDIO DO BRASIL C., Ingaramo A., Keltai K., Lanas F., LEROY J.E.A.N., LITVAK BRUNO M.R., Liu L., Lonn E.M., LUCIARDI H.L., LUQUEZ H.U.G.O., MACIN S.M., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Maia L.N., MAJUL C.R., MANENTI E., Metsarinne K.P., Montaña O., NANI S., Novaretto L., O’Donnell M., Parkhomenko A.N., PELAGAGGE M.J., Precoma D.B., RECH R., Reis G., ROSSI DOS SANTOS F., ROSSI P., SALA J., SARAIVA J.O.S.E., SARJANOVICH R.J., SCHIAVI L.B., SCHROE H., SCHYGIEL P.O., Torp-Pedersen C., VAN DE BORNE P., VAN DEN HEUVEL P.A.U.L., Varigos J.D., VENSENTINI N., Verhamme P.B., VICO M., VITA N.A., VOGEL D., VRANCKX P., Widimsky P., Yusoff K., Yusuf S., ZAIDMAN C., ZIMMERMANN S.L.Fuentes:googlescopus